EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

AR, the cell cycle, and prostate cancer

Steven P Balk, Karen E Knudsen

Nuclear Receptor Signaling · 2008-01 · 6 (1)

DOI: 10.1621/nrs.06001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nuclear Receptor Signaling, online erschienen am 01.02.2008. Verfasst von Steven P Balk und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Program-Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Androgen Receptor Antagonists. Die Arbeit wurde bisher 220-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The androgen receptor (AR) is a critical effector of prostate cancer development and progression. The dependence of this tumor type on AR activity is exploited in treatment of disseminated prostate cancers, wherein ablation of AR function (achieved either through ligand depletion and/or the use of AR antagonists) is the first line of therapeutic intervention. These strategies are initially effective, and induce a mixed response of cell cycle arrest or apoptosis in prostate cancer cells. However, recurrent, incurable tumors ultimately arise as a result of inappropriately restored AR function. Based on these observations, it is imperative to define the mechanisms by which AR controls cancer cell proliferation. Mechanistic investigation has revealed that AR acts as a master regulator of G1-S phase progression, able to induce signals that promote G1 cyclin-dependent kinase (CDK) activity, induce phosphorylation/inactivation of the retinoblastoma tumor suppressor (RB), and thereby govern androgen-dependent proliferation. These functions appear to be independent of the recently identified TMPRSS2-ETS fusions. Once engaged, several components of the cell cycle machinery actively modulate AR activity throughout the cell cycle, thus indicating that crosstalk between the AR and cell cycle pathways likely modulate the mitogenic response to androgen. As will be discussed, discrete aberrations in this process can alter the proliferative response to androgen, and potentially subvert hormonal control of tumor progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen Receptor AntagonistsAndrogen AntagonistsCell CycleCell ProliferationCyclin-Dependent KinasesGenes, Tumor SuppressorHumansMaleNeoplasms, Hormone-DependentPhosphorylationProstate-Specific AntigenProstatic NeoplasmsReceptors, AndrogenRetinoblastoma Protein

Substanzen

AR protein, humanAndrogen AntagonistsAndrogen Receptor AntagonistsReceptors, AndrogenRetinoblastoma ProteinCyclin-Dependent KinasesProstate-Specific Antigen

Autor:innen und Institutionen

  • Cancer Biology Program-Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Förderung

  • NCI NIH HHS
  • NIEHS NIH HHS

Zitieren

APA

Balk, S. P., & Knudsen, K. E. (2008). AR, the cell cycle, and prostate cancer. Nuclear Receptor Signaling, 6(1). https://doi.org/10.1621/nrs.06001

Vancouver

Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nuclear Receptor Signaling. 2008;6(1). doi:10.1621/nrs.06001

BibTeX
@article{Balk2008,
  author = {Balk, Steven P and Knudsen, Karen E},
  title = {AR, the cell cycle, and prostate cancer},
  journal = {Nuclear Receptor Signaling},
  year = {2008},
  volume = {6},
  number = {1},
  doi = {10.1621/nrs.06001}
}
Kostenlos starten →